Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    [A32041] It was developed by MCPRF and FDA first approved in September 2012. … Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.

  2. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … , peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655].

  3. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
  4. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … , resulting in a premature termination of the trial.

  5. Drug

    Methylnaltrexone

    go.drugbank.com/drugs/DB06800
    ApprovedInvestigational

    It is also a weak CYP2D6 inhibitor. FDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.

  6. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    [A185420] It is used to restore serotonergic function in the treatment of depression and anxiety. … escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in

    Products: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg Filmtabletten
  7. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. … Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood.

  8. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis.

  9. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [L24474] It is an agonist of the melanocortin 4 receptor.

  10. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.